Aberrant O-GlcNAcylation characterizes chronic lymphocytic leukemia

Y. Shi, J. Tomic, F. Wen, S. Shaha, A. Bahlo, R. Harrison, J. W. Dennis, R. Williams, B. J. Gross, S. Walker, J. Zuccolo, J. P. Deans, Gerald Warren Hart, D. E. Spaner

Research output: Contribution to journalArticle

Abstract

O-linked N-Acetylglucosamine (O-GlcNAc) post-translational modifications originate from the activity of the hexosamine pathway, and are known to affect intracellular signaling processes. As aberrant responses to microenvironmental signals are a feature of chronic lymphocytic leukemia (CLL), O-GlcNAcylated protein levels were measured in primary CLL cells. In contrast to normal circulating and tonsillar B cells, CLL cells expressed high levels of O-GlcNAcylated proteins, including p53, c-myc and Akt. O-GlcNAcylation in CLL cells increased following activation with cytokines and through toll-like receptors (TLRs), or after loading with hexosamine pathway substrates. However, high baseline O-GlcNAc levels were associated with impaired signaling responses to TLR agonists, chemotherapeutic agents, B cell receptor crosslinking and mitogens. Indolent and aggressive clinical behavior of CLL cells were found to correlate with higher and lower O-GlcNAc levels, respectively. These findings suggest that intracellular O-GlcNAcylation is associated with the pathogenesis of CLL, which could potentially have therapeutic implications.

Original languageEnglish (US)
Pages (from-to)1588-1598
Number of pages11
JournalLeukemia
Volume24
Issue number9
DOIs
StatePublished - Sep 2010

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Hexosamines
Toll-Like Receptors
Mitogen Receptors
Acetylglucosamine
Post Translational Protein Processing
Proteins
B-Lymphocytes
Cytokines

Keywords

  • chronic lymphocytic leukemia
  • glucosamine
  • glycolysis
  • hexosamine pathway
  • signal transduction

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine
  • Medicine(all)

Cite this

Shi, Y., Tomic, J., Wen, F., Shaha, S., Bahlo, A., Harrison, R., ... Spaner, D. E. (2010). Aberrant O-GlcNAcylation characterizes chronic lymphocytic leukemia. Leukemia, 24(9), 1588-1598. https://doi.org/10.1038/leu.2010.152

Aberrant O-GlcNAcylation characterizes chronic lymphocytic leukemia. / Shi, Y.; Tomic, J.; Wen, F.; Shaha, S.; Bahlo, A.; Harrison, R.; Dennis, J. W.; Williams, R.; Gross, B. J.; Walker, S.; Zuccolo, J.; Deans, J. P.; Hart, Gerald Warren; Spaner, D. E.

In: Leukemia, Vol. 24, No. 9, 09.2010, p. 1588-1598.

Research output: Contribution to journalArticle

Shi, Y, Tomic, J, Wen, F, Shaha, S, Bahlo, A, Harrison, R, Dennis, JW, Williams, R, Gross, BJ, Walker, S, Zuccolo, J, Deans, JP, Hart, GW & Spaner, DE 2010, 'Aberrant O-GlcNAcylation characterizes chronic lymphocytic leukemia', Leukemia, vol. 24, no. 9, pp. 1588-1598. https://doi.org/10.1038/leu.2010.152
Shi Y, Tomic J, Wen F, Shaha S, Bahlo A, Harrison R et al. Aberrant O-GlcNAcylation characterizes chronic lymphocytic leukemia. Leukemia. 2010 Sep;24(9):1588-1598. https://doi.org/10.1038/leu.2010.152
Shi, Y. ; Tomic, J. ; Wen, F. ; Shaha, S. ; Bahlo, A. ; Harrison, R. ; Dennis, J. W. ; Williams, R. ; Gross, B. J. ; Walker, S. ; Zuccolo, J. ; Deans, J. P. ; Hart, Gerald Warren ; Spaner, D. E. / Aberrant O-GlcNAcylation characterizes chronic lymphocytic leukemia. In: Leukemia. 2010 ; Vol. 24, No. 9. pp. 1588-1598.
@article{e07e6909d0b2462384c2717d9f53d9ae,
title = "Aberrant O-GlcNAcylation characterizes chronic lymphocytic leukemia",
abstract = "O-linked N-Acetylglucosamine (O-GlcNAc) post-translational modifications originate from the activity of the hexosamine pathway, and are known to affect intracellular signaling processes. As aberrant responses to microenvironmental signals are a feature of chronic lymphocytic leukemia (CLL), O-GlcNAcylated protein levels were measured in primary CLL cells. In contrast to normal circulating and tonsillar B cells, CLL cells expressed high levels of O-GlcNAcylated proteins, including p53, c-myc and Akt. O-GlcNAcylation in CLL cells increased following activation with cytokines and through toll-like receptors (TLRs), or after loading with hexosamine pathway substrates. However, high baseline O-GlcNAc levels were associated with impaired signaling responses to TLR agonists, chemotherapeutic agents, B cell receptor crosslinking and mitogens. Indolent and aggressive clinical behavior of CLL cells were found to correlate with higher and lower O-GlcNAc levels, respectively. These findings suggest that intracellular O-GlcNAcylation is associated with the pathogenesis of CLL, which could potentially have therapeutic implications.",
keywords = "chronic lymphocytic leukemia, glucosamine, glycolysis, hexosamine pathway, signal transduction",
author = "Y. Shi and J. Tomic and F. Wen and S. Shaha and A. Bahlo and R. Harrison and Dennis, {J. W.} and R. Williams and Gross, {B. J.} and S. Walker and J. Zuccolo and Deans, {J. P.} and Hart, {Gerald Warren} and Spaner, {D. E.}",
year = "2010",
month = "9",
doi = "10.1038/leu.2010.152",
language = "English (US)",
volume = "24",
pages = "1588--1598",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Aberrant O-GlcNAcylation characterizes chronic lymphocytic leukemia

AU - Shi, Y.

AU - Tomic, J.

AU - Wen, F.

AU - Shaha, S.

AU - Bahlo, A.

AU - Harrison, R.

AU - Dennis, J. W.

AU - Williams, R.

AU - Gross, B. J.

AU - Walker, S.

AU - Zuccolo, J.

AU - Deans, J. P.

AU - Hart, Gerald Warren

AU - Spaner, D. E.

PY - 2010/9

Y1 - 2010/9

N2 - O-linked N-Acetylglucosamine (O-GlcNAc) post-translational modifications originate from the activity of the hexosamine pathway, and are known to affect intracellular signaling processes. As aberrant responses to microenvironmental signals are a feature of chronic lymphocytic leukemia (CLL), O-GlcNAcylated protein levels were measured in primary CLL cells. In contrast to normal circulating and tonsillar B cells, CLL cells expressed high levels of O-GlcNAcylated proteins, including p53, c-myc and Akt. O-GlcNAcylation in CLL cells increased following activation with cytokines and through toll-like receptors (TLRs), or after loading with hexosamine pathway substrates. However, high baseline O-GlcNAc levels were associated with impaired signaling responses to TLR agonists, chemotherapeutic agents, B cell receptor crosslinking and mitogens. Indolent and aggressive clinical behavior of CLL cells were found to correlate with higher and lower O-GlcNAc levels, respectively. These findings suggest that intracellular O-GlcNAcylation is associated with the pathogenesis of CLL, which could potentially have therapeutic implications.

AB - O-linked N-Acetylglucosamine (O-GlcNAc) post-translational modifications originate from the activity of the hexosamine pathway, and are known to affect intracellular signaling processes. As aberrant responses to microenvironmental signals are a feature of chronic lymphocytic leukemia (CLL), O-GlcNAcylated protein levels were measured in primary CLL cells. In contrast to normal circulating and tonsillar B cells, CLL cells expressed high levels of O-GlcNAcylated proteins, including p53, c-myc and Akt. O-GlcNAcylation in CLL cells increased following activation with cytokines and through toll-like receptors (TLRs), or after loading with hexosamine pathway substrates. However, high baseline O-GlcNAc levels were associated with impaired signaling responses to TLR agonists, chemotherapeutic agents, B cell receptor crosslinking and mitogens. Indolent and aggressive clinical behavior of CLL cells were found to correlate with higher and lower O-GlcNAc levels, respectively. These findings suggest that intracellular O-GlcNAcylation is associated with the pathogenesis of CLL, which could potentially have therapeutic implications.

KW - chronic lymphocytic leukemia

KW - glucosamine

KW - glycolysis

KW - hexosamine pathway

KW - signal transduction

UR - http://www.scopus.com/inward/record.url?scp=77956422977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956422977&partnerID=8YFLogxK

U2 - 10.1038/leu.2010.152

DO - 10.1038/leu.2010.152

M3 - Article

C2 - 20668475

AN - SCOPUS:77956422977

VL - 24

SP - 1588

EP - 1598

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 9

ER -